Actively Recruiting
Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-01-07
144
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating Vasorin (Vasn) as a new biomarker for diagnosing and predicting outcomes in patients with septic shock, the most severe form of infection-related shock. This study compares plasma Vasn levels between two groups: patients with septic shock and patients experiencing non-septic shock such as post-cardiac surgery vasoplegia or other types of shock without infection. The goal is to see if Vasn provides better diagnostic accuracy than current markers like procalcitonin and to assess its link with patient survival over 28 days. Participants are divided into two groups based on their shock type: septic shock with infection and non-septic shock without infection. Blood samples will be taken to measure Vasn concentrations at day 0, day 1, and day 3. Researchers will also correlate Vasn levels with clinical factors including noradrenaline dose, kidney injury occurrence, coagulation markers, organ failure scores (SOFA), and length of hospital stay. During the study, patients admitted to intensive care for less than 24 hours will have blood drawn to assess Vasn levels and other laboratory markers. The study will track how Vasn levels relate to illness severity, treatment needs, and survival over the first three days and up to 28 days after admission. This information aims to help improve diagnosis and treatment decisions for patients with different types of shock.
CONDITIONS
Brief Title
Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults over 18 years
- Patients admitted for less than 24 hours in intensive care unit of the CHU Amiens Picardie
- Group 1: Patients with septic shock defined by sepsis with lactate ≥ 2 mmol/l, requiring vasopressors to maintain mean blood pressure at 65 mmHg despite adequate vascular filling, with fever (temperature >38.3°C) and documented or suspected infection
- Group 2: Patients with shock defined by arterial hypotension requiring vasopressors with lactate ≥ 2 mmol/l but without suspected infection and no fever (temperature <38°C), including examples such as vasoplegia post cardiac surgery with cardiopulmonary bypass, cardiogenic shock, or hemorrhagic shock
You will not qualify if you...
- Pregnant women
- Group 1: No evidence of suspected or documented infection
- Group 2: Presence of fever and/or suspected infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 days
Participants provide blood samples to measure concentrations of circulating Vasorin and to assess correlations with various clinical parameters during septic shock or shock without sepsis.
Blood samples collected on Days 0, 1, and 3
Duration - Up to 3 months
Participants are observed for clinical outcomes related to Vasorin levels, including mortality, length of hospitalization, and organ function scores.
Follow-up assessments depending on hospitalization length
Trial Site Locations
Total: 1 location
1
CHU Amiens-Picardie
Amiens, France, 80000
Actively Recruiting
Research Team
J
Julien Maizel, Pr
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here